PURE Bioscience Reports Fiscal First Quarter 2025 Financial Results

On December 16, 2024, Pure Bioscience, Inc. (OTCQB: PURE) announced in a press release its financial results for the fiscal first quarter ended October 31, 2024. The company disclosed that net product sales for this quarter were $555,000, a decrease from the $718,000 reported for the same period in the previous year. The decline in sales was primarily attributed to budgetary constraints from a major end-use customer.

For the fiscal first quarter ended October 31, 2024, Pure Bioscience reported a net loss of $689,000, a slight improvement from the $735,000 loss in the corresponding period in 2023. Excluding share-based compensation, the net loss for the quarter was $632,000, compared to $655,000 in the prior year’s quarter. Earnings per share for the fiscal first quarter of both 2024 and 2023 were recorded at ($0.01).

In a statement, Robert Bartlett, Chief Executive Officer of Pure Bioscience, emphasized the company’s commitment to expanding its business strategy through key distributor partnerships. Despite a lower first-quarter revenue compared to the previous year, Bartlett highlighted efforts focused on engaging new distributors, providing training, and bolstering product marketing in the food and beverage sector.

Pure Bioscience continues to concentrate on advancing its proprietary antimicrobial products, primarily within the food and beverage industry, utilizing its patented technology centered around non-toxic silver dihydrogen citrate (SDC). The company’s technology platform aims to address health and environmental challenges posed by pathogens and hygienic control.

Pure Bioscience’s detailed financial results, including its condensed consolidated balance sheets as of October 31, 2024, and July 31, 2024, along with the condensed consolidated statements of operations and cash flows for the three months ended October 31, 2024 and 2023, were also included in the filing.

Investors are advised to exercise caution with forward-looking statements as inherent risks and uncertainties could cause actual results to differ from projections. The Company’s periodic report filings with the Securities and Exchange Commission provide further elaboration on these factors.

Mark Elliott, VP of Finance at Pure Bioscience, can be reached for further inquiries at 619-596-8600 ext.: 116.

The company’s official business address is 771 Jamacha Rd. #512, El Cajon, California 92019. Additional information on Pure Bioscience can be accessed at www.purebio.com.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read PURE Bioscience’s 8K filing here.

PURE Bioscience Company Profile

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.